3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Prostatic Neoplasms, Castration-Resistant
1
Nonseminomatous germ cell tumor
1
Neoplasms
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Interventions
Prednisone
5
Docetaxel
4
niraparib
2
enzalutamide
2
darolutamide
2
Pluvicto
2
Abiraterone Acetate
2
olaparib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
cabazitaxel
1
abiraterone
1
Rosuvastatin Calcium
1
Pioglitazone
1
Omeprazole
1
JNJ-64619178
1
JNJ-64264681
1
Dexamethasone
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
cabazitaxel
×
90 days
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled